Steve Lendaris is a full-service life science intellectual property lawyer; assisting clients with strategic patent counseling, post-grant proceedings before the U.S. Patent Trial and Appeal Board (PTAB), and intellectual property litigation. Clients, from universities and small start-ups to large multinational corporations, regularly turn to Steve for advice on a broad range of biotechnology-related issues, from therapeutic antibody development and manufacturing to novel strategies for nucleic acid sequencing. Steve is a frequent lecturer on the use of PTAB proceedings in the life sciences and has spoken extensively on the evolving standard of patent eligibility in the field.
In addition to strategic management of their patent portfolios, clients often retain Steve for assistance with IP diligence matters. Whether it is the review of a competitor's patent portfolio, the purchase of a royalty stream, or the acquisition of an entire enterprise, clients rely on Steve to handle to the deep dives into highly technical areas of science and law to ensure that both IP value and IP risk are appropriately considered.
Before attending law school, Steve performed his graduate school research on the protein-nucleic acid interactions underlying pre-messenger RNA splicing. Prior to graduate school, he was an assistant process development scientist at a large pharmaceutical company working on the manufacture of recombinant blood clotting factors.